Kolon TissueGene (950160) Q4 2024 earnings summary

Executive summary

• Focus on cell and gene therapy platform TG-C, targeting osteoarthritis and related degenerative diseases, with U.S. Phase 3 clinical trials completed for knee OA and Phase 2/1 approvals for hip OA and DDD, respectively.

• Diversified operations include a health & beauty distribution business in Korea, contributing to revenue growth.

• Significant R&D investment continues, with a robust pipeline and global partnerships for manufacturing and clinical operations.

Financial highlights

• 2024 revenue: $3.72M, up 31% YoY, driven by growth in the distribution segment.

• Operating loss widened to $16.1M (from $15.7M in 2023), mainly due to increased legal and R&D expenses.

• Net loss: $24.8M, up from $13.2M in 2023, impacted by derivative valuation losses on convertible bonds.

• Cash and equivalents at year-end: $0.5M, down from $21.3M, reflecting heavy R&D and operational outflows.

• Equity increased to $99.3M, supported by new share issuances and convertible bond conversions.

Outlook and guidance

• Completion of Phase 3 knee OA trials positions TG-C for BLA submission after 2-year follow-up and data analysis.

• Expansion into hip OA and DDD indications, with further clinical trials planned.

• Continued investment in R&D and manufacturing scale-up for anticipated commercialization.

• Ongoing legal risks from unresolved lawsuits related to past product issues.